SK Biopharmaceuticals Co., Ltd
http://www.skbp.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From SK Biopharmaceuticals Co., Ltd
What’s Next At Dr Reddy’s: Biologics CDMO, Cell And Gene Therapy Push
Indian firms are getting their act together in areas like cell and gene therapy, with Dr Reddy’s aiming big and readying a facility alongside an alliance with a Chinese firm for a CAR-T therapy. The company is also doubling down in contract development and manufacturing, with an eye on opportunities in biologics.
Time To Shop? SK Sees ‘Biggest Opportunity’ For Biotech Investment
At a recent forum in Seoul, SK Group unveiled its biotech investment strategy and noted the next few years could present multiple major opportunities for Korean biotechs.
Asia Deal Watch: Astellas, GO Team Up On Targeted Cancer Therapy
Astellas subsidiary Xyphos will partner with GO to discover novel antibodies against two glycoprotein targets. SciNeuro picks up abandoned GSK programs in cardiovascular medicine for potential use in the neurodegeneration space.
Korea Q1 Roundup: Overseas Sales, COVID Prove Positive In Mixed Results
Among recent highlights, SK Bioscience files for approval of recombinant protein COVID-19 vaccine GBP510, Hanmi Pharmaceutical’s Chinese subsidiary continues to report strong earnings, led by cold drug sales, while Yuhan’s novel peptide drug candidate for degenerative disc disease is set to move into a Phase III trial in the US.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
-
Drug Discovery Tools
- ADMET
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- SK Holdings
- SK Life Science, Inc.
- SK Biofarm Co., Ltd.